FABP5 regulates an immunosuppressive microenvironment in hepatocellular carcinoma through the NF-κB/PD-L1 axis
5 affiliations
- 1The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, People’s Republic of China
- 2The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, Guangdong, China
- 3Department of Acupuncture, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China
- 4Department of Radiology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
- 5Dongguan Key Laboratory of Traditional Chinese Medicine Hepatology, the Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China
Abstract
Background: Fatty acid binding protein 5 (FABP5) contributes to lipid metabolism and inflammation, but, its immunoregulatory role in hepatocellular carcinoma (HCC) is unclear. Considering the strong metabolic–immune interplay in HCC, elucidating how FABP5 shapes the tumor immune microenvironment may uncover new therapeutic targets. Methods: TCGA, CCLE and single-cell RNA-seq datasets were employed to characterize FABP5 expression and clinical relevance. FABP5 knockdown was performed to assess effects on HCC cell proliferation. Immune infiltration, immune checkpoint profiles, TIDE scores and enrichment of immune-related pathways were analyzed. Differentially expressed genes underwent GO and KEGG pathway enrichment analyses. Protein–protein docking, molecular dynamics (MD) simulations and in vitro assays were conducted to explore the regulatory role of FABP5 in the NF-κB/PD-L1 axis. Drug screening, molecular docking and duplicate MD simulations were carried out to identify potential FABP5-targeting compounds. Results: FABP5 was significantly upregulated in HCC and predicted worse survival, serving as an independent prognostic factor. Single-cell analysis identified predominant FABP5 expression in fibroblasts and macrophages. FABP5 knockdown suppressed cell proliferation, colony formation, DNA synthesis and migration, accompanied by decreased expression of epithelial–mesenchymal transition (EMT) markers. FABP5-high tumors exhibited increased immune infiltration but raised immune checkpoint levels and higher TIDE scores, indicative of an immunosuppressive microenvironment. FABP5 correlated positively with NF-κB pathway genes and molecular docking predicted stable complexes between IκBα and P65. Experimental validation confirmed that FABP5 drives PD-L1 upregulation in an NF-κB–dependent manner. Drug screening identified CZS-241 as the most promising FABP5-binding candidate, and duplicate MD simulations demonstrated a stable FABP5–CZS-241 complex. Conclusion: FABP5 drives immunosuppression in HCC by inducing PD-L1 via the NF-κB pathway. CZS-241 is identified as a promising FABP5-targeting compound with therapeutic potential for HCC.
Related
- A macrophage-associated immunosuppressive subtype defined by Lactobacillus/Bifidobacterium-associated host genes characterizes prognosis and the immune microenvironment in hepatocellular carcinoma.
- ADAMTS3 Promotes Hepatocellular Carcinoma Cell Growth and Migration Through TGF-β:TGFBR2 Signaling
- Tumor-Associated Mast Cells Drive Immunosuppression and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4-mediated Regulatory T-Cell Recruitment.
- Elucidating the toxicogenomic mechanisms of DBP exposure on Hepatocellular carcinoma through network toxicology and molecular docking analysis
- Nanoparticle-Based Therapies for Turning Cold Tumors Hot : How to Treat an Immunosuppressive Tumor Microenvironment
BibTeX
@article{an2026fabp5,
title = {{FABP5 regulates an immunosuppressive microenvironment in hepatocellular carcinoma through the NF-κB/PD-L1 axis}},
author = {Rui An and Shibing Hou and Min Hong and Jiaorong Zhen and Zhijuan Wang and Haoming Huang and Weixuan Zhao and Mianmian Liao and Weiqu Yuan and Danping Huang},
journal = {PLOS One},
year = {2026},
month = sep,
doi = {10.1371/journal.pone.0356359},
url = {https://doi.org/10.1371/journal.pone.0356359},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - FABP5 regulates an immunosuppressive microenvironment in hepatocellular carcinoma through the NF-κB/PD-L1 axis
AU - Rui An
AU - Shibing Hou
AU - Min Hong
AU - Jiaorong Zhen
AU - Zhijuan Wang
AU - Haoming Huang
AU - Weixuan Zhao
AU - Mianmian Liao
AU - Weiqu Yuan
AU - Danping Huang
PY - 2026
DA - 2026/09/29
JO - PLOS One
DO - 10.1371/journal.pone.0356359
UR - https://doi.org/10.1371/journal.pone.0356359
AB - Background: Fatty acid binding protein 5 (FABP5) contributes to lipid metabolism and inflammation, but, its immunoregulatory role in hepatocellular carcinoma (HCC) is unclear. Considering the strong metabolic–immune interplay in HCC, elucidating how FABP5 shapes the tumor immune microenvironment may uncover new therapeutic targets. Methods: TCGA, CCLE and single-cell RNA-seq datasets were employed to characterize FABP5 expression and clinical relevance. FABP5 knockdown was performed to assess effects on HCC cell proliferation. Immune infiltration, immune checkpoint profiles, TIDE scores and enrichment of immune-related pathways were analyzed. Differentially expressed genes underwent GO and KEGG pathway enrichment analyses. Protein–protein docking, molecular dynamics (MD) simulations and in vitro assays were conducted to explore the regulatory role of FABP5 in the NF-κB/PD-L1 axis. Drug screening, molecular docking and duplicate MD simulations were carried out to identify potential FABP5-targeting compounds. Results: FABP5 was significantly upregulated in HCC and predicted worse survival, serving as an independent prognostic factor. Single-cell analysis identified predominant FABP5 expression in fibroblasts and macrophages. FABP5 knockdown suppressed cell proliferation, colony formation, DNA synthesis and migration, accompanied by decreased expression of epithelial–mesenchymal transition (EMT) markers. FABP5-high tumors exhibited increased immune infiltration but raised immune checkpoint levels and higher TIDE scores, indicative of an immunosuppressive microenvironment. FABP5 correlated positively with NF-κB pathway genes and molecular docking predicted stable complexes between IκBα and P65. Experimental validation confirmed that FABP5 drives PD-L1 upregulation in an NF-κB–dependent manner. Drug screening identified CZS-241 as the most promising FABP5-binding candidate, and duplicate MD simulations demonstrated a stable FABP5–CZS-241 complex. Conclusion: FABP5 drives immunosuppression in HCC by inducing PD-L1 via the NF-κB pathway. CZS-241 is identified as a promising FABP5-targeting compound with therapeutic potential for HCC.
SN - 1932-6203
ER -